COMMUNIQUÉS West-GlobeNewswire

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

02/10/2019 - 15:00

SAN DIEGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and [...]

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

02/10/2019 - 15:00

Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETEC Naval Medical Research Center will [...]

Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

02/10/2019 - 15:00

Initiative during 2019 baseball postseason highlights Chris’ personal story and the profound consequences that can result from OA knee pain BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics ( [...]

XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis

02/10/2019 - 14:59

Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies AUSTIN, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced the first [...]

Eyenovia to Participate in Multiple Upcoming Medical Meetings

02/10/2019 - 14:30

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print [...]

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

02/10/2019 - 14:30

NOVATO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases [...]

CellaVision completes the acquisition of RAL Diagnostics

02/10/2019 - 14:30

The information was released for public disclosure on October 2, 2019, at 14:30 CET CellaVision has completed the previously announced acquisition of RAL Diagnostics, a company focused on the production and sale of [...]

Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock

02/10/2019 - 14:27

MINNEAPOLIS, Minn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced the pricing of its previously announced public offering of its common stock, [...]

Dabir Surfaces Inc. Announces Master Product Agreement with Trinity Health

02/10/2019 - 14:26

CHICAGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Dabir Surfaces Inc., a subsidiary of Methode Electronics Inc. (NYSE: MEI), focused on improving patient outcomes through the design and manufacture of an innovative solution [...]

REPEAT - AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures

02/10/2019 - 14:03

VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]

AgraFlora Organics présente les améliorations réalisées sur l'infrastructure du Delta Greenhouse Complex incluant des dépenses en immobilisations corporelles de plus de 30 millions de dollars canadiens

02/10/2019 - 14:03

VANCOUVER, Colombie-Britannique, 02 oct. 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (« AgraFlora » ou la « Société ») (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) une société internationale de [...]

Celldex Therapeutics Announces Upcoming Data Presentations

02/10/2019 - 14:01

HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and [...]

BioCardia Announces the Appointment of Two New Board Members

02/10/2019 - 14:00

SAN CARLOS, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of [...]

Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference

02/10/2019 - 14:00

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate [...]

Demant A/S: Change of date of publication of Interim Management Statement

02/10/2019 - 09:53

Company announcement no 2019- 12 2 October 2019 Change of date of publication of Interim Management Statement The date of publication of Demant’s Interim Management Statement has been changed from 7 November to 18 [...]

AgraFlora Organics Reviews Delta Greenhouse Infrastructure Upgrades; Deploys Over C$30,000,000 in PPE Expenditures

02/10/2019 - 09:01

VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF ), a growth oriented and diversified [...]

New Data Presented on ASLAN’s varlitinib at ESMO 2019

02/10/2019 - 08:30

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of new data from a phase [...]

Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution

02/10/2019 - 08:00

Company announcement, Helsinki 2 October 2019 at 9.00 AM (EEST) Nexstim Plc in Technology Licensing Discussions with a Leading California Based Academic Institution Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or " [...]

Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost

02/10/2019 - 07:30

Press Release Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost NCX 470 met the primary endpoint of non- [...]